Our goal is the generation of novel vaccines directed against chronic diseases and beyond.
Building on the proprietary WISIT platform technology, we are currently developing such therapeutic neoglucoconjugate vaccines for three indications, with Parkinson’s disease as our lead indication and aggregated aSynuclein as prime target molecule.